Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Anaesthetic drugs are used for avoiding pain during surgical procedures. There are various specially designed equipment like anaesthetic vaporizer which are used in surgical procedures. The anaesthetic vaporizer is used as inhalational anaesthetic along with nasal oxygen is set for delivering the oxygen. The anaesthesia is generally required in all types of surgical procedures. They work by restraining nerve signal which help in keeping patient awake and avoid it from going into brain. At the state of induced sleep, the surgical procedures are carried out without the patient feeling anything. After the removal of anaesthesia nerve signals are able to reach brain and consciousness is returns.
The Europe general anaesthetic drug market is witnessing lucrative growth during the forecast period 2021-2027. The anaesthetic drugs induces inhibition of nerve ending by blocking conduction in peripheral nerves. It is achieved by anaesthetic as they bind reversibly and inactivates the sodium channels. The major factors like surgical complexities and patient safety expectation is propelling the market growth of Europe general anaesthetic drug market. Rising launch of new products is also refuelling the market growth of Europe general anaesthetic drug market. However, few anaesthetic doctors and certified anaesthetic nurses is hindering the market growth of Europe general anaesthetic drug market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the general anaesthetic drug market. In addition, complete analysis of changes on general anaesthetic drug expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Europe economies, international trade, business investments, GDP and marketing strategies of key players present in the market. There is slight slow growth of general anaesthetic drug market is experienced during the COVID-19 situation as there is several restraining factors like mismatch between demand and supply due to complete shutdown in many countries which hampered the transportation of general anaesthetic drugs. The several surgical procedures are post ponded during the time of COVID-19 pandemic. However, activities are resuming and all the pending surgeries are being held nowadays. The market acquired its original state and witnessing rapid growth during the forecast period 2021-2027.
The Europe general anaesthetic drug market is segmented by drug molecules, route of administration, end user and country.
Drug Molecules like isoflurane, desflurane, sevoflurane, ketamine, thiopental, opioids, propofol and other are comprised in Europe general anaesthetic drug market. In which ketamine is also contributing in the market growth. The ketamine is also called as the dissociated anaesthesia. It induces a trance-like state which implies pain relief, sedation and amnesia. The chief distinguishing features of ketamine are preserved breathing and respiratory reflexes, stimulated heart function with high blood pressure and slight bronchodilation. It comes under the class III scheduled drug which is allowed to use in hospitals and medical centres as an anaesthetic agent.
The route of administration of anaesthetic drugs like intravenous and inhalational are comprised in the Europe general anaesthetic drug market. In which intravenous route is likely to dominate the market in 2020. The intravenous anaesthetic have advantage over volatile techniques like better recovery profile with reduced risk of post-operative nausea and vomiting along with facilitation of intraoperative wake up while retaining amnesia. The most frequent agent used by intravenous route is propofol. Its effects is generally improved with use of opioids like remifentanil.
The end users like hospitals, speciality clinics and ambulatory surgical centres are comprised in the Europe general anaesthetic drug market. In which ambulatory surgical centres are also contributing in the market growth. The ambulatory surgical centres provides same day surgical procedure to the outpatients. The rising rate of surgeries is propelling growth of segment. Increase in number of ambulatory surgical centres is also refuelling the market growth of Europe general anaesthetic drug market. The surgical complexities and patient safety expectation is also elevating the market growth of Europe general anaesthetic drug market.
Country wise the Europe general anaesthetic drug market is studied for countries like UK, Germany, Spain, Italy and France. In which UK is anticipated to dominate the region in 2020. The rising adoption of technological advancement is propelling the growth of region. Rising launch of new anaesthetic drug is also refuelling the market growth of Europe general anaesthetic drug market. The rising government initiative for patient safety is also elevating the market growth of Europe general anaesthetic drug market.
The major key players in general anaesthetic drug market are Baxter International Inc. (Us), Hikma Pharmaceuticals Plc (Uk), Pfizer Inc. (Us), Piramal Enterprises Limited (India), Abbvie (Us), Fresenius Se & Co. Kgaa (Germany), Par Pharmaceutical (Us), Teva Pharmaceuticals (Israel), Viatris/Mylan (Us), Novartis Ag (Us), Abbott Laboratories (Us), Astrazeneca Plc (Us), F. Hoffmann-La Roche (Switzerland), Glaxosmithkline Plc (Uk), Gilead Sciences Inc. (Us), Bayer Ag (Germany), Merck & Co. Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (Us), Akorn (Us) and Apotex (Canada) among other are analysed.
August 2020: The Fresenius Kabi got approval for their first medication with smart label included with radio-frequency identification technology. Which is a first RFID smart labelled product, Diprivan (propofol) 200mg per 20mL (10mg per mL) injectables Emulsion, USP.
July 2020: The Acacia Pharma a group of PLC received the U.S. FDA permission for BYFAVO (remimazolam) for injection for induction and maintenance of procedural sedation in adults undergoing procedures which lasts up to 30 minutes or less.
May 2020: Hikma Pharmaceutical PLC, a multinational pharmaceutical company, announced their propofol injectable emulsion, USP in various quantities 20ml, 50ml, 100ml.
January 2020: Novartis AG take over Aspen’s Japanese operations focused on generics and off-patent medicines.
The study comprised of general anaesthetic drug market. In which study analysed the various segments of the market. The general anaesthetic drug market is bifurcated by drug molecule, route of administration and end users. The study also comprised of dominating segment of the market. In the study it is profound that the drug molecule segment is dominated by propofol. Likewise, route of administration is dominated by intravenous route and end user segment is dominated by hospitals. The study also imparts the geographical section of the market and it concludes that United Kingdom is dominating the market in 2020. The study also comprised of impact on COVID-19 on the general anaesthetic drug market and it conclude that there is slight slow growth of general anaesthetic drug market is experienced during the COVID-19 situation as there is several restraining factors like mismatch between demand and supply due to complete shutdown in many countries which hampered the transportation of general anaesthetic drugs. The several surgical procedures are post ponded during the time of COVID-19 pandemic. However, activities are resuming and all the pending surgeries are being held nowadays. The market acquired its original state and witnessing rapid growth during the forecast period 2021-2027. The study also imparts the major key players operating in the regions.
Why to buy this report
